

Retrophin, Inc. Investor Relations Department 12255 El Camino Real Suite 250 San Diego, CA 92130 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: RTRX Last Trade: 20.76 Trade Time: 4:00 PM ET Jul 26, 2017 Change: 0.41 ♣ (+2.015%) Day Range 20.28 - 20.86 52-Week Range 15.55 - 24.57 Volume 198,120

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Retrophin, Inc. (NASDAQ: RTRX) is a publicly-traded, San Diego-based biopharmaceutical company focused on the discovery, acquisition, development and commercialization of drugs for the treatment of debilitating and often lifethreatening diseases for which there are currently limited patient options. The Company is currently focused on several catastrophic diseases affecting children, including Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), and others.

Retrophin is currently enrolling patients in a potentially pivotal Phase ... (more)

Stock Performance



Press Releases [View all]

Jul 26, 2017

Retrophin to Report Second Quarter 2017 Financial Results

Jul 25, 2017

Retrophin Commences Patient Dosing in International, Registrational Phase 3 Trial of RE-024 in PKAN

Jun 1, 2017

Retrophin Announces Expansion of
Intellectual Property Estate for Sparsentan
with Newly Issued Patents in the United
States and Europe

May 25, 2017

Retrophin Announces Presentations for Late-Stage Clinical Development Programs at Upcoming Medical Congresses

May 23, 2017

Retrophin to Present at the Jefferies 2017 Global Healthcare Conference

Financials [View all]

Second Quarter Financial Results

Mar 1, 2017

Annual Report (10-K)

Apr 14, 2017

Proxy Statement (DEF 14A)

May 5, 2017

Quarterly Report (10-Q)

Nov 4, 2016

Quarterly Report (10-Q)

Aug 5, 2016

Quarterly Report (10-Q)